US equities |
NVDA $168.89 ▲+0.00% MU $725.11 ▲+0.00% SNDK $859.99 ▲+0.00% AMD $515.21 ▲+0.00% CRWV $48.73 ▲+0.00% SPCX $143.09 ▲+0.00% TSLA $379.78 ▲+0.00% SKHY $129.66 ▲+0.00%
FinancialContent

Gilead Sciences (NQ:GILD)

170.87 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
From Gabelli Funds
Via GlobeNewswire
News headline image
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Third Quarter 2026 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
From Gilead Sciences, Inc.
Via Business Wire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
From Gilead Sciences, Inc.
Via Business Wire
News headline image
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
From Gilead Sciences, Inc.
Via Business Wire
Global Drugmakers Earmark Billions to Ramp Up Their US Footprint
Via Investor Brand Network
Topics World Trade
News headline image
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
From Gilead Sciences, Inc.
Via Business Wire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
News headline image
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >